The metabolism and disposition of
LY186641, a diarylsulfonylurea with
antineoplastic activity identified in preclinical tests, was determined in 21 patients who received 23 courses of orally administered
drug. A linear correlation was found between the dose of
drug administered and
LY186641 peak plasma concentrations and
LY186641 area under the curve measurements. Clearance (135 +/- 36 ml/h/m2), terminal half-life (31 +/- 11 h), and volume of distribution (10.2 +/- 2.8 liters) were independent of
drug dose. No
LY186641 was excreted in urine. Hydroxy and keto metabolites of
LY186641 were identified in plasma and urine samples. Urinary excretion of these metabolites during the initial 48 h following
drug administration accounted for 20% of
LY186641 disposition. Plasma half-life of the hydroxy and keto metabolites was longer than that of parent
drug (3.3 and 3.1 days, respectively). Plasma concentrations of parent
drug correlated with the presence of
methemoglobinemia, the dose-limiting toxicity found with
LY186641.